Jasper Ridge Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

Jasper Ridge Partners’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-9,184	Closed	-$270K	–	76
2018 Q3	$270K	Hold	9,184	–	–	0.01%	69
2018 Q2	$418K	Hold	9,184	–	–	0.03%	53
2018 Q1	$485K	Hold	9,184	–	–	0.03%	48
2017 Q4	$625K	Hold	9,184	–	–	0.04%	44
2017 Q3	$757K	Hold	9,184	–	–	0.04%	53
2017 Q2	$860K	Hold	9,184	–	–	0.05%	53
2017 Q1	$585K	Buy	9,184 +4,592	+100%	+$279K	0.04%	67
2016 Q4	$204K	Buy	+4,592	New	+$162K	0.01%	91
2015 Q4	–	Sell	-4,592	Closed	-$422K	–	93
2015 Q3	$422K	Sell	4,592 -9,643	-68%	-$835K	0.03%	69
2015 Q2	$1.25M	Buy	+14,235	New	+$1.22M	0.09%	49
2014 Q4	–	Sell	-8,495	Closed	-$385K	–	108
2014 Q3	$385K	Hold	8,495	–	–	0.03%	83
2014 Q2	$352K	Hold	8,495	–	–	0.02%	103
2014 Q1	$588K	Sell	8,495 -5,740	-40%	-$422K	0.04%	85
2013 Q4	$858K	Hold	14,235	–	–	0.05%	70
2013 Q3	$865K	Hold	14,235	–	–	0.05%	66
2013 Q2	$953K	Buy	+14,235	New	+$640K	0.06%	64

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Jasper Ridge Partners's CLVS Position: Q4 2018 in Review

Jasper Ridge Partners sold out of Clovis Oncology, Inc. (CLVS) in Q4 2018, closing a stake of 9,184 shares — an estimated $270K sold.

Jasper Ridge Partners first reported a position in CLVS in Q2 2013 and held it in 16 quarters. The position peaked at $1.25M in Q2 2015. 165 funds tracked by Wall St. Rank hold CLVS as of Q4 2018.

Jasper Ridge Partners reported no remaining Clovis Oncology, Inc. position as of Q4 2018 after selling out during the quarter.
Jasper Ridge Partners sold 9,184 Clovis Oncology, Inc. shares in Q4 2018, an estimated $270K.
Jasper Ridge Partners first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 16 quarters.
Jasper Ridge Partners's Clovis Oncology, Inc. position peaked at $1.25M in Q2 2015.
165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2018.

Based on Jasper Ridge Partners's 13F filing for Q4 2018, filed 13 Feb 2019.